Injury to or neurodegeneration of the optic nerve underlies vision loss in many diseases, including glaucoma, ischemic and traumatic optic neuropathies, as well as retinal artery or vein occlusions, and many others. Normally, in humans and indeed in all mammals, there is no regenerative response, and the failure of injured or degenerating retinal ganglion cells (RGCs) to reconnect their axons through the optic nerve to their natural targets in the brain explains the irreversibility of such vision loss. A full white paper was published by these authors and is available on the National Eye Institute (NEI) Web site (in the public domain; available at <https://nei.nih.gov/audacious/optic_nerve>).

The NEI\'s Audacious Goals Initiative (AGI) program was initiated in 2012, searching for big ideas to bring the energy of the eye and vision research community into a chosen single audacious goal: to restore vision by regenerating neurons and their neural connections in the eye and visual system. To understand progress to date in the sciences relevant to optic nerve regeneration, and more specifically to identify focal areas for funding, the NEI convened a workshop in November 2014 in Washington, DC. Participants (see appendix) represented a variety of research areas relevant to optic nerve regeneration, from developmental neurobiology to visual processing. Over the course of a 4-hour roundtable discussion, the workshop reviewed the current state of the science and addressed knowledge gaps in and barriers to scientific progress ([Tables 1](#i1552-5783-57-3-1271-t01){ref-type="table"} and [2](#i1552-5783-57-3-1271-t02){ref-type="table"}), and identified key areas for discovery research.
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Gaps in Knowledge and Other Unknowns
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Barriers to Progress/Current Needs
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Steps to Optic Nerve Regeneration {#s2}
=================================

What will it take to restore vision in optic neuropathies, and what must happen to rescue an injured or dying RGC? Workshop participants outlined steps necessary for promoting successful optic nerve regeneration and restoration of vision.

RGC Survival {#s2a}
------------

Survival is obviously a requirement for cellular or axon regeneration; thus, preventing RGCs from degeneration and subsequent death in the face of injury or disease is a critical first step. Retinal ganglion cell response to insult was also discussed, as the molecular pathophysiology of different insults, be they glaucomatous, ischemic, traumatic, inflammatory, or others, is still the subject of intense investigation. Although such questions hold great promise, developing therapeutic approaches to restore vision may not always require a complete understanding of the underlying causes of disease. Considerable progress in dissecting molecular pathways involved with RGC death in a number of preclinical models of human diseases has been made,^[@i1552-5783-57-3-1271-b01],[@i1552-5783-57-3-1271-b02]^ although translational testing in humans with various optic neuropathies has been slow to follow.

A related area of considerable interest is RGC-type specificity. Retinal ganglion cells can be divided into different types based on morphology, receptive field properties, and more recently, by genetic markers.^[@i1552-5783-57-3-1271-b03],[@i1552-5783-57-3-1271-b04]^ Important questions were identified as high priority: do different RGC types exhibit varying degrees of vulnerability to injury or disease? Do some types show more regenerative capacity than others?

Axon Growth {#s2b}
-----------

Both short (across an injury site) and long distance growth (back to central visual targets) must be addressed and may involve separate signaling pathways. Considerable progress has been made in identifying candidate molecules that stimulate axons to grow across an optic nerve injury site.^[@i1552-5783-57-3-1271-b05],[@i1552-5783-57-3-1271-b06]^ Manipulation of local glial, vascular, and inflammatory responses all deserve additional attention, and testing combinatorial therapies and evaluating the quality of regenerative growth, including axon guidance, remain largely unexplored and should represent a major objective of the AGI. Indeed, the next major challenge is to encourage long distance growth to appropriate targets while minimizing aberrant growth and sprouting.^[@i1552-5783-57-3-1271-b07],[@i1552-5783-57-3-1271-b08]^ While much progress has been made to understand the mechanisms underlying guidance, target selection, and synapse formation of developing axons, little is known about how regenerating axons perform after injury.^[@i1552-5783-57-3-1271-b06],[@i1552-5783-57-3-1271-b09],[@i1552-5783-57-3-1271-b10]^ Workshop participants generally dismissed the requirement that regenerative axon growth should necessarily recapitulate developmental patterning regarding pathway choice, target selection from the dozen different subcortical targets for regenerating RGCs to choose from,^[@i1552-5783-57-3-1271-b11]^ or specificity of synaptic connectivity.^[@i1552-5783-57-3-1271-b12]^ In regenerating axons, what steps need to be taken to prevent an aberrant projection from developing and innervating the spared/undamaged retina or inappropriate areas in the brain? Since target selection is cell-type specific, getting specific RGC types to innervate the appropriate target and become reintegrated into existing or remodeled circuits may be crucial, although questions on circuit reintegration in the adult are largely unstudied. Thus, it will be important to identify guidance cues and synapse formation signaling pathways in a regenerative environment. Indeed, some axon growth--promoting regenerative therapies may introduce guidance or synapse formation problems, while others may not, suggesting that all regenerative therapies may not be equal. Within this context, however, there was discussion that RGC innervation of brain targets subserving image formation may be more important than promoting regeneration of RGCs dedicated to non--image-forming functions such as pupillary light response or photoentrainment of circadian rhythm.

Gaps in Scientific Knowledge and Barriers to Progress {#s3}
=====================================================

The workshop\'s subsequent focus was to identify and elaborate on the present gaps of knowledge in the area of optic nerve regeneration; these are summarized in [Table 1](#i1552-5783-57-3-1271-t01){ref-type="table"}. Closely related to these gaps in knowledge was the discussion of which of these are significant barriers to progress, summarized in [Table 2](#i1552-5783-57-3-1271-t02){ref-type="table"}. Overcoming these gaps will help bring scientists together across disciplines to make major progress toward optic nerve regeneration and vision restoration.

Translation to Human Disease {#s4}
============================

Perhaps most limiting in reaching the goal of restoring vision in humans is the lack of translational research and early phase human testing in RGC survival and regeneration. Research across other body systems has already demonstrated that human testing is extremely important, and certainly human patients with optic nerve diseases are eager to participate in appropriately vetted trials of new therapeutic candidates. Such initial testing of candidate therapies in humans will begin to address critical questions, such as: How important are fine points of circuit integration? Is it enough to give someone light perception or improve contrast sensitivity? Functional improvement is a big step, but it will also be necessary to perform human trials to learn how to measure axon regeneration and visual restoration in patients. Similarly, the workshop participants noted that, as a field, we should think backwards from the "clinic-of-the-future." Having biomarkers for RGC function will be extremely important, as will having a delivery system with demonstrated safety. Moving treatments into human testing was identified as something that could be done quickly, within 5 years, and would help the field determine how to conduct clinical trials in a shorter time frame.

A View to the Future {#s5}
====================

Based on workshop consensus, immediate goals should include extending work to enhance regeneration in current animal models, solving axon guidance and central targeting in regeneration, and crossing into human testing for both validating biomarkers and testing candidate therapies. Other first-move approaches should include building resource centers and expanding functional or behavioral testing assays in preclinical models. The group appreciated that although disease pathophysiology remains an important separate goal, one therapeutic solution might ultimately address many different optic neuropathies, and that identifying candidate therapies should be a major focus of the AGI.
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